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OBJECTIVE — Insulin resistance has been reported in up to 70% of women with polycystic
ovary syndrome (PCOS). Physiologic and genetic data currently implicate post–insulin receptor
signalingdefectsinsubstratessuchasglycogensynthasekinase3(GSK3).TheAKT2genewas
chosen as a candidate for PCOS because its product affects glucose metabolism and mitogenic
signaling, interacts with GSK3, and mediates cell survival in the ovary.
RESEARCH DESIGN AND METHODS — Subjects were recruited from the reproduc-
tive endocrinology clinic at the University of Alabama at Birmingham, and control subjects were
recruited from the surrounding community; 287 white women with PCOS and 187 white
control subjects were genotyped for four single nucleotide polymorphisms (SNPs) in AKT2.
GenotypingtookplaceatCedars-SinaiMedicalCenterinLosAngeles.SNPsandhaplotypeswere
tested for association with PCOS risk and phenotypic markers of PCOS.
RESULTS — Minor allele carriers of SNPs rs3730051 and rs8100018 had increased odds of
PCOS (odds ratio [OR] 2.2, P  0.004, and 2.4, P  0.001, respectively). The haplotype
T-G-C-T was signiﬁcantly associated with PCOS (OR 2.0, P  0.01). Carriers of the risk hap-
lotypes for both AKT2 and GSK3B had a further increased odds of PCOS (OR 3.1, P  0.005).
CONCLUSIONS — These data suggest that polymorphisms in two components of the in-
sulin signaling pathway, AKT2 and GSK3B, are associated with PCOS. The presence of multiple
lesions in a single pathway may confer increased risk.
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P
olycystic ovary syndrome (PCOS),
characterized by hyperandro-
genism, oligo-ovulation, and poly-
cystic ovarian morphology, affects 7% of
women (1). Inherent in PCOS is a pro-
found peripheral insulin resistance, ob-
servedinupto70%ofwomenwithPCOS
(2). The molecular basis of this intrinsic
resistance remains unknown, but postin-
sulin receptor defects appear to contrib-
utetothepathophysiologyofbothinsulin
resistance and hyperandrogenemia (2).
The insulin signaling pathway includes
two main pathways: a metabolic arm
through the activation of phosphatidylino-
sitol 3-kinase (PI3K) and a mitogenic arm
acting via mitogen-activated protein kinase
(3). The expression and activity of down-
stream targets of PI3K have been investi-
gated in PCOS tissues, with distinct
molecular defects in post–insulin receptor
signaling identiﬁed in ﬁbroblasts and adi-
pose tissues of women with PCOS (4).
Akt, also known as protein kinase B,
participatesininsulinsignalingviaactiva-
tion by 3-phosphoinositide–dependent
kinase, which is activated by the product
of PI3K, phosphatidylinositol 3,4,5-
trisphosphate (5). Three highly con-
served genes encode the forms of Akt,
Akt1, Akt2, and Akt3 (5). Akt2 is the ma-
jor form involved in insulin signaling in
adipose tissue and is required for net gain
in surface GLUT4 in response to insulin
signaling (6).
Akt2 is widely expressed and partici-
pates in insulin metabolism, mitogenic sig-
naling, and apoptosis (5). Activation of Akt
byinsulininadipocytesisreducedintype2
diabetes (5), and experimental reduction of
Akt2 leads to decreased insulin sensitivity
and reduced glucose disposal (3), both of
which are features of PCOS. Insulin-
stimulated Akt phosphorylation is reduced
by 40–60% in PCOS skeletal muscle com-
pared with matched control muscle (7).
In response to insulin signaling, Akt2
phosphorylates and inhibits glycogen syn-
thase kinase 3 (GSK3), which facilitates
glycogen synthesis (8). Physiological data
indicate that insulin-stimulated glycogen
synthesis is impaired in PCOS ﬁbroblasts
(9) and cultured ovarian granulosa cells
(10). In PCOS adipocytes, GSK3 tyrosine
phosphorylation is increased and insulin-
stimulated serine phosphorylation is de-
creased (11), which could result in an
overactiveGSK3thatislessabletobesup-
pressed by insulin, possibly explaining im-
paired insulin-stimulated glycogen
synthesis. Aberrant GSK3 expression and
activity has also been reported in PCOS
ovarian theca, with overexpression of
GSK3 stimulating 17-hydroxylase activ-
ity of P450c17 (12). Based on these physi-
ological data, we previously genotyped
GSK3B for association between polymor-
phismsinthegeneandPCOSandidentiﬁed
a risk haplotype (13).
In the current study, we continued
this line of investigation by examining
whether variants in AKT2 were associated
with susceptibility to PCOS or the bio-
chemical features of PCOS. Analysis re-
vealed associations between the minor
allele of two single nucleotide polymor-
phisms(SNPs)fromAKT2andPCOSsus-
ceptibility.Thepresenceoftheseallelesin
a haplotype spanning the AKT2 gene re-
gion was also associated with PCOS.
RESEARCH DESIGN AND
METHODS
Subjects and phenotyping
A total of 287 consecutive unrelated white
patients with PCOS and 187 unrelated
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the Birmingham, Alabama, area. Case pa-
tients were recruited from the reproductive
endocrine practice of one of the investiga-
tors (R.A.) at the University of Alabama at
Birmingham. Participation in research was
offeredtopatientsmeetingtheinclusioncri-
teria (being premenopausal and nonpreg-
nant, having undergone no hormonal
therapy [including oral contraceptives] for
at least 3 months, and meeting the 1990
National Institutes of Health criteria for
PCOS [14]). The comprehensive physical
examinationandhormonalevaluationused
in our research have been described in de-
tail previously (15).
Control subjects were healthy women,
withregularmenstrualcyclesandnofamily
history of hirsutism. These women had no
hirsutism,acne,alopecia,orendocrinedys-
function and had not undergone hormonal
therapy (including oral contraceptives) for
at least 3 months before testing. Control
subjects were recruited by word of mouth
and advertisements in the Birmingham, Al-
abama, area through a call for “healthy
women” without detailing the nature of the
studies.
All subjects gave written informed
consent. The study was performed ac-
cording to the guidelines of the institu-
tional review boards of the University of
AlabamaatBirminghamandCedars-Sinai
Medical Center.
SNP genotyping and haplotype
determination
We selected four SNPs (rs11671439,
rs8100018, rs3730051, and rs2304188)
that span the 51.5-kb genomic length of
AKT2atchromosome19q13.1–13.2.These
were selected because they are predicted to
tag the haplotypes (across the entire gene,
plus 10 kb upstream and 10 kb down-
stream) occurring at 1% frequency in the
Caucasian population of the HapMap data-
base (16). The four SNPs were genotyped
using the 5-exonuclease assay (TaqMan
MGB;AppliedBiosystems,FosterCity,CA)
(17); duplicate genotyping of 96 samples
for one SNP yielded 100% concordance.
The genotyping success rate was 92.5%.
Haploview 3 (18) was used to deter-
mine haplotypes as well as haplotype
blocks, with an accelerated expectation
maximization algorithm. Haploview was
also used to calculate linkage disequilib-
rium (LD) (the D statistic) between each
pairwise combination of all the SNPs.
Haplotypes were assigned to individual
subjects only when the assignment could
be made with 95% certainty.
Statistical analysis
Unpaired t tests and 
2 tests were used to
compare clinical characteristics between
women with and without PCOS; quanti-
tative trait values were log- or square
root–transformed as appropriate to re-
duce non-normality.
Association of SNPs or haplotypes with
presenceorabsenceofPCOSwasevaluated
using logistic regression, with adjustment
forBMIandageineveryanalysis.ANCOVA
was used for association between genotype
and quantitative traits, again with adjust-
ment for age and BMI. Signiﬁcance was
takenatP0.017toaccountfortheeffects
of multiple testing, considering that we an-
alyzed one LD group of SNPs against three
families of traits (PCOS diagnosis, andro-
gens, and metabolic traits), yielding a cor-
rection factor of 3 (i.e., three independent
comparisons).
In exploratory analyses, various multi-
ple logistic regression models were used to
explorethecontributionofAKT2haplotype
to PCOS risk while simultaneously consid-
ering the risk haplotype from GSK3B (13).
Analyses were performed with Statview 5.0
(SAS Institute, Cary, NC).
RESULTS— Clinical features of the
cohortaregiveninTable1.StrongLD(D
0.95) was observed among each of the
four AKT2 SNPs (Table 2, Fig. 1). Minor
allele carriers of two SNPs had an in-
creased frequency of PCOS. The presence
of the G allele at rs8100018 conferred an
odds ratio (OR) of 2.4 (95% CI 1.4–4.1,
P0.001),whereasthepresenceoftheG
allele at rs3730051 conferred an OR of
2.2 (95% CI 1.3–3.7, P  0.004). There
were no signiﬁcant associations with any
quantitative traits.
Five haplotypes, comprising SNPs
rs11671439,rs8100018,rs3730051,and
rs2304188, accounted for 99% of the
population (Table 3). There was a signif-
icant association between haplotype T-G-
C-T and PCOS (OR 2.0, 95% CI 1.1–3.4,
P  0.01). This haplotype includes the
minor alleles of both rs8100018 and
rs3730051, the two SNPs associated with
PCOS. There were no signiﬁcant associa-
Table 1—Clinical features of women with PCOS and control subjects
Control PCOS
n 187 287
Age (years) 33.0 (17.0) 27.5 (11.5)*
BMI (kg/m
2) 24.1 (6.4) 34.7 (13.5)*
WHR 0.78 (0.08) 0.83 (0.10)*
mFG score 0 (0) 7.0 (5.0)*
Hirsute (%) 0 73.9*
Total testosterone (nmol/l) 1.42 (0.92) 2.77 (1.07)*
Free testosterone (pmol/l) 12.1 (9.0) 29.1 (16.3)*
DHEAS (mol/l) 2.58 (2.03) 5.66 (4.61)*
SHBG (nmol/l)† 220.0 (120.0) 150.0 (70.0)*
Insulin (pmol/l) 49.5 (45.9) 129.15 (129.2)*
Glucose (mmol/l) 4.77 (0.56) 4.77 (0.72)
HOMA-IR 0.92 (0.83) 2.29 (1.93)*
HOMA-%B 103.9 (59.5) 175.3 (99.3)*
Data are median (interquartile range). *P  0.001 compared with control group. †SHBG activity was
measuredbycompetitivebindinganalysisusingSephadexG-25and	
3H
testosteroneastheligand;thisassay
gives values of approximately 100–300 nmol/l in normal adult women. DHEAS, dehydroepiandrosterone
sulfate; HOMA-%B, -cell function estimated by the homeostasis model assessment; HOMA-IR, insulin
resistance estimated by the homeostasis model assessment; mFG score, modiﬁed Ferriman-Gallwey hirsut-
ism score; SHBG, sex hormone–binding globulin; WHR, waist-to-hip ratio.
Table 2—SNP location and frequency data
Variant Location
Alleles
(major/minor)
Overall
MAF PCOS MAF
Control
MAF
rs11671439 Intron 1 C/T 0.078 0.068 0.088
rs8100018 Intron 4 C/G 0.262 0.296 0.216
rs3730051 Intron 8 A/G 0.221 0.247 0.180
rs2304188 Intron 10 C/T 0.153 0.141 0.178
MAF, minor allele frequency.
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titative traits.
GSK3B was previously analyzed for as-
sociation with PCOS susceptibility (13).
The nine-SNP haplotype C-A-C-C-G-G-A-
G-GwassigniﬁcantlyassociatedwithPCOS
(OR 1.7, 95% CI 1.03–2.85, P  0.028)
and was the most common haplotype
among the white subjects with PCOS but
the second most common in control sub-
jects. Taking into account the previous as-
sociation between GSK3B haplotype and
PCOS, we conducted exploratory analyses
with a set of logistic regression models that
simultaneously considered AKT2 and
GSK3B (Table 4). The ﬁrst model was de-
signed to evaluate the independence of the
risk haplotypes of both AKT2 and GSK3B
on PCOS susceptibility. In this model, each
risk haplotype retained a signiﬁcant associ-
ation with PCOS (AKT2 risk haplotype car-
riers, OR 2.1, P  0.01; GSK3B risk
haplotype carriers OR 1.8, P  0.036),
demonstrating independence. In the next
logisticregressionwithPCOSasthedepen-
dent variable, the independent variables
were age, BMI, and number of risk haplo-
types(foreachsubject,rangingfrom0to4).
This analysis revealed that each additional
risk haplotype conferred a 58% increase in
the odds of PCOS (P  0.01). In the ﬁnal
combined model, carriers of both risk hap-
lotypes had an increased odds of PCOS
comparedwithsubjectswithneitherhaplo-
type (OR 3.1, P  0.005).
CONCLUSIONS— Our data demon-
stratethatpolymorphismsintheAKT2gene
are signiﬁcantly associated with PCOS. The
minor alleles of rs3730051 and rs8100018
were associated with PCOS, and the corre-
sponding haplotype was also associated
with PCOS. We used independent, addi-
tive,andcombinedlogisticregressionmod-
els to demonstrate that the association
between AKT2 haplotype T-G-C-T and
PCOS was independent of the GSK3B risk
haplotype, but PCOS risk was increased
when both were present. These data offer
twopotentialsusceptibilitylocifromthein-
sulin signaling pathway that may confer in-
creased PCOS risk and suggest that the
presenceofmultiplelesionsinasinglepath-
way confers increased risk.
The signiﬁcant association of rs3735001
and rs8100018 with PCOS extends to a
haplotype that includes the minor alleles
of these two AKT2 SNPs. Carriers of both
minor alleles, in a haplotype, had the
same OR as carriers of either risk allele
alone,asaSNP.Thisﬁndingsuggeststhat
these alleles are markers tagging the same
variant in the gene region. The unknown
functional variant can be a coding variant
or a noncoding variant that alters AKT2
promoter activity or mRNA transport and
stability, resulting in changes in protein
expression.
Our analyses did not show any signiﬁ-
cant associations with quantitative traits re-
lated to glucose homeostasis. This was also
thecaseforGSK3B(13).Becauseanalysesto
detect association between quantitative
traits and genotype are conducted only
within women with PCOS, the reduced
samplemayhavedecreasedpowertodetect
an effect. Also, in our cohort insulin resis-
tancewasquantiﬁedviahomeostaticmodel
assessment, which may be insufﬁciently re-
ﬂective of insulin resistance to allow detec-
tion of association with genetic variants.
Analysis in a larger cohort or one character-
ized by physiological studies (e.g., euglyce-
mic clamp) would be necessary to
deﬁnitively rule out whether there is an as-
sociation of AKT2 variants with insulin re-
sistance and whether such a relationship
mediates the effect of genetic variants on
PCOSrisk.Alternatively,whereasAkt2and
GSK3are best known for their role in glu-
cose uptake (5), it is possible that their role
in PCOS does not manifest as an alteration
in androgen levels or metabolic distur-
bance, but in other pathways not reﬂected
intypicalquantitativetraits.Aktisknownto
participate in several pathways including
inﬂammation, lipogenesis, and endothelial
function (5), and it is possible that aberrant
function in these pathways contributes to
the pathophysiology of PCOS.
Aktisexpressedingranulosaandtheca
cells of primordial follicles and is involved
in signal transduction, cell cycle, and cell
fate (19,20). Recent studies have shown al-
teredratesofapoptosisinPCOSovariantis-
Figure 1—Gene structure and LD plot for
AKT2. A: The gene structure of AKT2 is
shown; the gene has 14 exons and is located on
the reverse strand of chromosome 19q13. The
locations of the genotyped SNPs relative to the
exonsareindicated.B:TheLDplotdisplaysD
values (percent) for each pair of SNPs in the
box at the intersection of the diagonals from
each SNP. D between each pair of SNPs was
1.0 (solid boxes) and was 0.98 between
rs3730051 and rs8100018, indicating strong
LD across the region.
Table 3—Haplotype frequency data in the
women with PCOS and control subjects
Haplotype
Overall
frequency
PCOS
frequency
Control
frequency
T-A-G-T 0.504 0.497 0.517
T-G-C-T 0.216 0.240 0.176
C-A-G-T 0.154 0.138 0.181
T-A-G-C 0.075 0.067 0.088
T-A-C-T 0.047 0.053 0.037
Table 4—Logistic regression models simultaneously considering AKT2 and GSK3B in PCOS
risk
Model Independent variables OR (95% CI) P value
Independence Carrier state (Y/N) for AKT2 risk
haplotype*
2.10 (1.2–3.7) 0.010
Carrier state (Y/N) for GSK3B risk
haplotype*
1.80 (1.0–3.1) 0.036
Additive Number of AKT2 or GSK3B risk
haplotypes†
1.58 (1.1–2.2) 0.010
Combined Carrier state (Y/N) for both risk haplotypes
in AKT2 and GSK3B‡
3.11 (1.4–6.9) 0.0050
PCOS diagnosis was the dependent variable in all models. Each analysis also included age and BMI as
independent variables. *Carriers are homozygous or heterozygous for risk haplotype (T-G-C-T inAKT2 and
C-A-C-C-G-G-A-G-GinGSK3B).†Numberofriskhaplotypesperindividualis0–4.‡Comparessubjectswhoare
carriers of at least one AKT2 risk haplotype and at least one GSK3B risk haplotype to all other subjects.
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(22). Overexpression of Akt2 has been
showntoresultinareducedrateofapopto-
sisinanumberofcelltypesincludingovary
(5) and is a potential causal factor in the
increased follicular growth and lack of atre-
sia associated with PCOS. Aberrant Akt2
andGSK3expressionandactivationcould
resultinincreasedcellsurvivalinPCOSfol-
licles and contribute to the theca cell hy-
pertrophy and abnormal follicular
development and promote the prolifera-
tion of granulosa. An increase in the latter
lessproliferativeandhighlysteroidogenic
cell type (23) could potentially increase
androgen production by the ovary, a
characteristic of PCOS. Increased basal,
luteinizing hormone- and insulin-
stimulated Akt phosphorylation has been
reported in PCOS ovarian theca (22),
with a subsequent increase in levels of
aromatase and luteinizing hormone re-
ceptor mRNA expression (20), resulting
in stimulation of granulosa cell prolifera-
tion. Increased serine and tyrosine phos-
phorylation of Akt in the ovary has been
demonstrated in an animal model exhib-
iting PCOS-like symptoms (24).
We have performed a number of ge-
neticassociationstudiesinthiscohort.Each
report represented a separate genotyping
experiment performed over the past several
years, testing an independent hypothesis;
therefore,eachwasanalyzedseparately.We
have published a positive association of
variants in six genes with PCOS (supple-
mental Table A1, available in an online ap-
pendix at http://dx.doi.org/10.2337/dc08-
0532). To assess the independence of these
associations and their relative signiﬁcance,
we conducted a logistic regression simulta-
neously analyzing all of the associated vari-
ants, with PCOS status as the dependent
variable(supplementalTableA2).Thisjoint
analysis revealed that the variants most sig-
niﬁcantly associated with PCOS were the
AKT2 and GSK3B risk haplotypes.
Two AKT2 SNPs and the haplotype
characterized by them were signiﬁcantly
associated with an increased odds of
PCOS. Genes with pleiotropic effects are
sensible candidates for PCOS, a syn-
drome characterized by dysfunction in
multiple systems. AKT2 is expressed in
several key PCOS tissues including adi-
posetissue,pancreas,andovaryandhasa
potential role in the regulation of insulin
signaling and glucose uptake, insulin se-
cretion,andcellproliferationintheovary,
all of which may be deranged in PCOS
(1). By examining multiple members of
a pathway that has been previously im-
plicated in both the genetics (13) and
physiology (11) of PCOS, we have dem-
onstrated that the presence of variants
in multiple members of a single path-
way may increase PCOS susceptibility.
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